A compound of formula, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R 1 represents 1H-Benzoimidazolyl; R 2 represents hydrogen; C 2-6 alkenyl; C 2-6 alkenylaryl; C 1-6 alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl and -C OH; aryl; carbocyclyl; heteroaryl; heterocyclyl which may optionally be substituted by one or more alkyl groups; C 1-6 alkylaryl; C 1-6 alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl aryl; or C R 4. wherein aryl is defined as phenyl optionally substituted with one or more substituents chosen from C 1-6 alkyl, C 1-6 alkoxy, halo, hydroxy and C 1-6 fluoroalkyl, or as naphthyl or 2-hydroxynaphthalen-1-yl; carbocyclyl is defined as cycloalkyl or cycloalkenyl, either of which may optionally be substituted with halogen (e.g. 1, 2 or 3 halogen atoms), hydroxyl -C O-C 1-4 alkyl, -C OH or 1 or 2 methyl groups; heteroaryl is defined as a 5- or 6-membered monocyclic or 9-10 membered bicyclic heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C O C 1-4 alkyl and C OH; or as 5-hydroxymethylfuran-2-yl or oxo-chromenyl; R 3 represents halogen; C 1-6 alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, C 1-6 alkoxy, C 1-6 thioalkyl, -C OH and -C O-C 1-6 alkyl; phenyl optionally substituted with one or more groups selected from halogen, hydroxyl, C 1-6 alkyl and C 1-6 alkoxy; naphthyl; heteroaryl optionally substituted with one or more groups selected from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy and -C OH;or -C R 5; R 4 represents C 1-6 alkyl or C 3-6 cycloalkyl; and R 5 represents C 1-6 alkyl, aryl, heteroaryl, -C 1-6 alkylaryl, -C 1-6 alkylheteroaryl, carbocyclyl, heterocyclyl, -C 1-6 alkylcarbocyclyl and -C 1-6 alkylheterocyclyl; wherein "carbocyclyl" is a non-aromatic saturated or partially saturated ring system; and wherein aryl groups may be optionally substituted with one or more groups selected from C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 alkoxy, halogen and hydroxy. or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R 1 represents 1H-Benzoimidazolyl; R 2 represents hydrogen; C 2-6 alkenyl; C 2-6 alkenylaryl; C 1-6 alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl and -C OH; aryl; carbocyclyl; heteroaryl; heterocyclyl which may optionally be substituted by one or more alkyl groups; C 1-6 alkylaryl; C 1-6 alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl aryl; or C R 4. wherein aryl is defined as phenyl optionally substituted with one or more substituents chosen from C 1-6 alkyl, C 1-6 alkoxy, halo, hydroxy and C 1-6 fluoroalkyl, or as naphthyl or 2-hydroxynaphthalen-1-yl; carbocyclyl is defined as cycloalkyl or cycloalkenyl, either of which may optionally be substituted with halogen (e.g. 1, 2 or 3 halogen atoms), hydroxyl -C O-C 1-4 alkyl, -C OH or 1 or 2 methyl groups; heteroaryl is defined as a 5- or 6-membered monocyclic or 9-10 membered bicyclic heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C O C 1-4 alkyl and C OH; or as 5-hydroxymethylfuran-2-yl or oxo-chromenyl; R 3 represents halogen; C 1-6 alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, C 1-6 alkoxy, C 1-6 thioalkyl, -C OH and -C O-C 1-6 alkyl; phenyl optionally substituted with one or more groups selected from halogen, hydroxyl, C 1-6 alkyl and C 1-6 alkoxy; naphthyl; heteroaryl optionally substituted with one or more groups selected from halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy and -C OH;or -C R 5; R 4 represents C 1-6 alkyl or C 3-6 cycloalkyl; and R 5 represents C 1-6 alkyl, aryl, heteroaryl, -C 1-6 alkylaryl, -C 1-6 alkylheteroaryl, carbocyclyl, heterocyclyl, -C 1-6 alkylcarbocyclyl and -C 1-6 alkylheterocyclyl; wherein "carbocyclyl" is a non-aromatic saturated or partially saturated ring system; and wherein aryl groups may be optionally substituted with one or more groups selected from C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 alkoxy, halogen and hydroxy.